Across TCGA pan-cancer cohorts, TRIM52 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRIM52 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher TRIM52 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM52 expression acts as an unfavorable survival marker.
COAD are the cancer types where TRIM52 Mutation most reproducibly stratifies survival.